SCHEMBL5652339

SCHEMBL5652339

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(Br)cc2)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.44
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 4/20 0.41
KDM4E B2RXH2 3/20 0.41
RAB9A P51151 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 3/20 0.41
HPGD P15428 4/20 0.40
ATM Q13315 1/20 0.40
POLB P06746 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CDC7 O00311 2/20 0.40
DBF4 Q9UBU7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650136 0.93 MAPT (0.51) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5650867 0.92 MAPT (0.47) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5652595 0.91 MAPT (0.45) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5652764 0.91 MAPT (0.45) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5652293 0.90 MAPT (0.44) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5654426 0.90 ALDH1A1 (0.50) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5647395 0.90 MAPT (0.50) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5652382 0.89 DCTPP1 (0.43) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5648376 0.88 MEN1 (0.47) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5654915 0.88 MAPT (0.43) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885ALDH1A1 1498/4885MEN1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.